Mitsubishi UFJ Asset Management
TCRR

Mitsubishi UFJ Asset Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,521
Closed -$132K – 1166
2021
Q3 		$132K Hold
15,521
– – ﹤0.01% 1094
2021
Q2 		$255K Buy
15,521
+2,822
+22% +$57K ﹤0.01% 1061
2021
Q1 		$280K Buy
12,699
+4,011
+46% +$109K ﹤0.01% 959
2020
Q4 		$269K Buy
+8,688
New +$220K ﹤0.01% 922

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mitsubishi UFJ Asset Management's TCRR Position: Q4 2021 in Review

Mitsubishi UFJ Asset Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 15,521 shares — an estimated $132K sold.

Mitsubishi UFJ Asset Management first reported a position in TCRR in Q4 2020 and held it in 4 quarters. The position peaked at $280K in Q1 2021. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Mitsubishi UFJ Asset Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 15,521 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $132K.
  • Mitsubishi UFJ Asset Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Mitsubishi UFJ Asset Management's TCR2 Therapeutics Inc. Common Stock position peaked at $280K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2021, filed 7 Feb 2022.